Elefante Mark B Boosts Stock Position in Eli Lilly and Company $LLY

Posted by Geri Gentry on Jun 17th, 2026

Eli Lilly and Company logo Elefante Mark B boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 33.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 2,898 shares of the company’s stock after acquiring an additional 726 shares during the quarter. Eli Lilly and Company comprises 1.9% of Elefante Mark B’s portfolio, making the stock its 23rd biggest holding. Elefante Mark B’s holdings in Eli Lilly and Company were worth $3,114,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Adalta Capital Management LLC boosted its holdings in Eli Lilly and Company by 17.5% during the 4th quarter. Adalta Capital Management LLC now owns 826 shares of the company’s stock valued at $888,000 after acquiring an additional 123 shares during the period. Delaney Dennis R boosted its holdings in Eli Lilly and Company by 28.6% during the 4th quarter. Delaney Dennis R now owns 2,849 shares of the company’s stock valued at $3,062,000 after acquiring an additional 633 shares during the period. Dempze Nancy E boosted its holdings in Eli Lilly and Company by 37.1% during the 4th quarter. Dempze Nancy E now owns 5,491 shares of the company’s stock valued at $5,901,000 after acquiring an additional 1,487 shares during the period. Notis McConarty Edward boosted its holdings in Eli Lilly and Company by 43.0% during the 4th quarter. Notis McConarty Edward now owns 3,464 shares of the company’s stock valued at $3,723,000 after acquiring an additional 1,041 shares during the period. Finally, Polar Capital Holdings Plc boosted its holdings in Eli Lilly and Company by 216.3% during the 4th quarter. Polar Capital Holdings Plc now owns 267,662 shares of the company’s stock valued at $287,651,000 after acquiring an additional 183,051 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on LLY shares. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Bank of America lifted their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Finally, Guggenheim reaffirmed a “buy” rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

View Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Trading Down 0.6%

Shares of NYSE LLY opened at $1,122.47 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business has a fifty day simple moving average of $1,006.08 and a two-hundred day simple moving average of $1,016.63. The firm has a market cap of $1.06 trillion, a PE ratio of 39.87, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly acquired 4E Therapeutics, a developer of non-opioid pain treatments, expanding its push into the painkiller market and broadening the company beyond obesity and diabetes drugs. Article Title
Positive Sentiment: The company announced several pipeline updates, including progress on oral and early-stage candidates and a Phase 1 Alzheimer’s program, reinforcing investor focus on Lilly’s deep R&D pipeline. Article Title
Positive Sentiment: Market research highlighting strong growth in the global GLP-1 receptor agonist market supports the long-term demand outlook for Lilly’s obesity and diabetes franchise, which remains a key driver of the stock. Article Title
Neutral Sentiment: Healthcare stocks were generally firmer in afternoon trading, providing a modest sector tailwind rather than a company-specific catalyst. Article Title
Neutral Sentiment: Several articles compared Lilly with Novo Nordisk amid ongoing obesity-drug competition, but these were mostly industry commentary and not new fundamental news for LLY. Article Title
Negative Sentiment: Investors are also weighing a “quiet new threat” to Lilly’s GLP-1 business, as employer coverage and access concerns could slow adoption or limit growth for its top-selling obesity drugs. Article Title

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.